June 21, 2017 8:35am

 

The real question is how much are algorithms in control

 

What’s not new?

 

Just because the sector gets out of whack doesn't mean you can make money …

 

Pre-open indication:  five (5), 2 BUY and 3 SELLS

 

A critical indication ahead of “our” universe’s open!

 

Are you a subscriber?  If not – you’re missing the realities of “our” universe! 

 


 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

 

Lower open expected

 

Dow futures are UP +0.02% and NASDAQ futures are UP 0.00%

 

U.S. stock index futures pointed to a slightly lower open on Wednesday, with investors keeping a close eye on moves in the oil market.

European markets moved lower shortly after it's open, as investors prepared for news out of the U.K. while keeping a close eye on the oil market for any sharp price moves.

Asian markets closed mostly lower following MSCI's decision to add mainland Chinese stocks to its emerging markets index gradually and as oil prices slipped around 2 percent overnight.

 

Data docket: mortgage applications are slated to come out at 7.00 a.m. ET, followed by existing homes sales at 10.00 a.m ET.

 

 

The cell therapy sector closed NEGATIVE on Tuesday, POSITIVE on Monday, NEGATIVE on Friday, Thursday and last Wednesday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

·         Tuesday closed barely NEGATIVE with 21 decliners, 20 advancers and 2 flat;

·         Monday closed POSITIVE with 7 decliners, 35 advancers and 1 flat;

·         Friday closed NEGATIVE with 26 decliners, 14 advancers and 3 flats;

·         Thursday closed NEGATIVE with 31 decliners, 10 advancers and 2 flats;

·         Last Wednesday closed NEGATIVE with 19 decliners, 18 advancers and 6 flats;

 

 

Remembering Tuesday’s closing bell newsletter, “Icarus is soaring even after a warning to not fly too low nor too high.”

  • Reiterating, “Remember a complacency warning as feathered share pricing melt in proximity to a hot market.”

 

My concern is … the IBB and its ability to stay UP beyond the pre-market indication  +0.10%…

•   Tuesday traded UP +1.27%

•   Monday +2.41%

•   Friday -0.36%

•   Thursday -0.77%

•   Wednesday +0.56%

•   Last Tuesday +0.41%

 

What did I see on Tuesday, the DOW closed DOWN -0.29% (-61.85) as the NASDAQ closed DOWN -0.82% (-50.98) … with the CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded again near 10.86 – UP +4.73% following Monday’s trading 10.24 down -1.35%

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed up +1.27% on Tuesday, and indicated a POSITIVE +0.22% in Wednesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Tuesday up +1.11%, and is indicating a POSITIVE +0.36% In Wednesday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +0.33% Tuesday, and is indicating a POSITIVE +0.05% in Wednesday’s pre-open;
  • The iShares Russell 2000 (IWM) closed down -1.01% on Tuesday, and indicating a POSITIVE +0.04% in Wednesday’s pre-open

 

 

Companies in my headlights:

………. We are back to measuring potential momentum for the sector …….

Juno Therapeutics (JUNO) closed up +$0.46 to $24.66 following Monday’s $24.20 (+$0.91). June started at $24.50; saw a high of $26.21 and a low of $21.68 having seen $24.20 twice in ten sessions.  The aftermarket indication was a positive +$0.14 or +0.57% - Maintaining BUY;

Kite Pharma (KITE) closed up +$1.92 to $91.21 following Monday’s $89.29 (+$1.44). June started at $74.66; saw a high of $89.71 and a low of $73.61.  The aftermarket indication is a positive +$0.79 or +0.87% - BUY;

Pluristem (PSTI) closed flat at $1.32. The aftermarket indication is a negative -$0.07 or 5.30% as Chinese based Innovative Medical walked away from a $30 M investment that was supposed to fund late-stage trials – Maintaining SELL;

Regenxbio (RGNX) closed up +$0.45 to $19.55 following Monday’s $19.10 (+$0.60). June started at $18.00; saw a high of $20.10 and a low of $18.00 having seen $19.10 twice in four sessions – Maintaining SELL;

Sangamo Therapeutics (SGMO) closed up +$0.25 to $8.20 following Monday’s $7.95 (+$0.50). June started at $7.00; saw a high of $7.95 and a low of $7.00 having seen $7.20 twice in twelve sessions.   SGMO announced an offering of common stock and the stock is selling-off -$0.75 or -9.15% in the pre-market – Maintaining SELL

 

 

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.